Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study

Background A phase I study found remarkable activity and manageable toxicity for doxorubicin (bolus) plus lurbinectedin (1-h intravenous [i.v.] infusion) on Day 1 every three weeks (q3wk) as second-line therapy in relapsed small cell lung cancer (SCLC). An expansion cohort further evaluated this com...

Descripción completa

Detalles Bibliográficos
Autores principales: Olmedo, María Eugenia, Forster, Martin, Moreno, Victor, López-Criado, María Pilar, Braña, Irene, Flynn, Michael, Doger, Bernard, de Miguel, María, López-Vilariño, José Antonio, Núñez, Rafael, Kahatt, Carmen, Cullell-Young, Martin, Zeaiter, Ali, Calvo, Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426303/
https://www.ncbi.nlm.nih.gov/pubmed/33704620
http://dx.doi.org/10.1007/s10637-020-01025-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426303/
https://www.ncbi.nlm.nih.gov/pubmed/33704620
http://dx.doi.org/10.1007/s10637-020-01025-x

Ejemplares similares